CADTH simeprevir (GALEXOS) news!

The Canadian Drug Review's CDEC Board approved simeprevir (GALEXOS) on June 18th, 2014, and has sent HepCBC a thank you letter for its simeprevir submission. Simeprevir (GALEXOS) is a new hepatitis C drug for genotype 1 infection which, at this point at least, is to be used in a triple therapy along with interferon alpha and ribavirin. This drug, developed by Janssen Pharmaceuticals and marketed in the USA as OLYSIO, is also being recommended in the US and

Vertex telaprevir (Incivik®) fatalities heighten concern over skin reactions

Dec. 19, 2012: Vertex Pharmaceutical announced that because of some recent fatalities among hepatitis C patients being treated with Vertex's telaprevir (Incivik®),  new warnings  have been placed on packaging about a potentially fatal skin reaction.  The current Standard of Care for hepatitis C patients with Genotype 1 is 'triple therapy': interferon plus ribavirin plus a protease inhibitor - either telaprevir or boceprevir (Merck's Victrelis®).  Note that